Universities and research institutes at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

83 universities and research institutes are at ENA 2026 — 112 presentations on the program. Most represented: University of Michigan (4 on the program), The Institute of Cancer Research (3 on the program), Masaryk University (3 on the program). 19 of them have their own page in this guide. As of Oct 13, 2026.

All 254 organizations at ENA 2026 →

Showing 1–12 of 83 organizations

Organization	ENA 2026 Attendance
University of Michigan Ann Arbor, MI
umich.edu Universities & institutes Public research university in Ann Arbor whose Rogel Cancer Center runs cancer research and clinical care.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Design Discovery of JZY3032, a First-in-Class DALTAC Rewiring AR-p300 Demonstrate Lineage-Selective Anti-tumor Efficacy in Advance Prostate Cancer Models Drug design Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents CRBN-Based Pan-KRAS PROTAC Degraders with Sub-Nanomolar Potency and Broad In Vivo Efficacy Across Clinically Relevant KRAS Mutant Tumors Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Discovery of clinical candidate SD-1240, a potent and selective STAT3 PROTAC degrader Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs Discovery of RPT04402, a first-in-class molecular glue activator with potent and selective anti-tumor activity in PPP2R1A mutant cancers Drug design
The Institute of Cancer Research London, UK
icr.ac.uk Universities & institutes London cancer research institute and college of the University of London, with a drug discovery centre; partnered with The Royal Marsden.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Dissecting tumour microenvironment signatures associated with chemoresistance in triple negative breast cancer Targeted agents Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Functional Genomics Targeted protein degradation models for the exploration of spliceosome-associated RNA helicases as therapeutic targets Genomics Session Thu Nov 19 5–6:30pm Workshop 6: Tumour microenvironment Immuno-oncology Talk Thu Nov 19 6–6:20pm Part of Workshop 6: Tumour microenvironment Exploiting fibroblast activation protein (FAP) in cancer therapy Immuno-oncology
Masaryk University Brno, Czech Republic
muni.cz Universities & institutes Public research university in Brno, Czech Republic, with faculties of medicine and science.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Profound changes of the p53 network induction on the translatome and proteome levels determine cellular response to MDM2 inhibition Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Optimizing p53/ISR-based cancer therapy through real-time in vivo monitoring of p53 activation Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Stiffness, stress, and stroma: patient-specific 3D spheroid models reveal biomechanical and cellular determinants of pancreatic cancer progression Preclinical models
Institute of Oncology Research (IOR) Bellinzona, Switzerland
ior.usi.ch Universities & institutes Cancer research institute affiliated with Università della Svizzera italiana, with programmes including lymphoma and prostate cancer.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Screening High-throughput synergy screening of blood-brain-barrier penetrant compounds identifies druggable targets that potentiate BTK inhibition in CNS lymphomas Preclinical models Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Transcriptional and epigenetic inducers of proximity as antitumor agents in marginal zone lymphomas Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents First characterization of the synthetic peptide CIGB-552 in B-cell lymphomas demonstrates antitumor activity in drug-resistant models and enhancement of BTK-targeted therapies Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents The CBP/EP300 inhibitor TT125-802 shows antitumor activity in marginal zone lymphoma models and can improve the effects of BTK inhibitors Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology FF01, a novel heavy chain antibody targeting the human endogenous retrovirus envelope, displays anti-lymphoma activity Immuno-oncology Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs BTK and BCL2 targeting with orelabrutinib (ICP-022) and mesutoclax (ICP-248): single-agent and combination activity in marginal zone lymphoma, including drug-resistant derivatives Drug design Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs Natural extracts show anti-proliferative activity in lymphoma cells with resistance to targeted agents Drug design
Centre de Recherche des Cordeliers Paris, France
crcordeliers.fr Universities & institutes Paris biomedical research centre run with Sorbonne Université, Université Paris Cité and Inserm.	Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Tumour immunology and inflammation Plasma complement activation is associated with favourable prognosis in luminal metastatic breast cancer Immuno-oncology Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Tumour immunology and inflammation Complement activation is associated with distinct functional states of membrane attack complex deposition in HER2-positive breast cancer Immuno-oncology
Children's Cancer Institute Sydney, Australia
ccia.org.au Universities & institutes Medical research institute focused on childhood cancer, including precision medicine and new treatments.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Functional Genomics Genome-wide Cas9 and subsequent focussed Cas13d screening identifies potential gene dependencies in diffuse midline glioma Genomics Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New agents for paediatric oncology Combined polyamine depletion and irinotecan drive durable tumour clearance in MYC-amplified Group 3 medulloblastoma Targeted agents
National Taiwan University Taipei, Taiwan
ntu.edu.tw Universities & institutes Public research university in Taipei with a college of medicine and a university teaching hospital.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Repurposing of HTS-10 to Overcome C797S-Mediated Osimertinib Resistance in EGFR-Mutant Lung Adenocarcinoma Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology Targeting the CD24–Siglec-10 Axis with S10FC Promotes Phagocytosis and Enhances Immunotherapy Efficacy in Lung Cancer Immuno-oncology
Toyo University Tokyo, Japan
toyo.ac.jp Universities & institutes Private university in Tokyo with faculties including life sciences.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Angiogenesis and vascular disrupting agents The effect of β-catenin on the selection of coactivators in HIF-α transcription Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Delivery modulation of AhR/Nrf2 signaling suppresses Wnt/β-catenin activity through competition for transcriptional co-activators in colorectal cancer Drug design
University of California, San Francisco San Francisco, CA
ucsf.edu Universities & institutes Health sciences university in San Francisco with a comprehensive cancer center and an academic medical center.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Molecular profiling A neural gene signature predicts recurrence of resected colorectal cancer liver metastases Genomics Talk Fri Nov 20 8:20–8:40am Part of Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Decoding CAR T cell function with CRISPR activation and interference Cell therapy
University of Edinburgh Edinburgh, UK
ed.ac.uk Universities & institutes Research university in Scotland whose Institute of Genetics and Cancer runs cancer research.	Session Fri Nov 20 9:30–10:45am Workshop 8: Proximity inducers beyond current PROTACs Drug design Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies First-in-class switch-control SRC/YES1 inhibitor NXP900 demonstrates potent synergy with KRAS inhibitors in drug-sensitive and resistant NSCLC models in vitro and in vivo Targeted agents
University of Helsinki Helsinki, Finland
helsinki.fi Universities & institutes Public research university in Finland with a faculty of medicine and cancer research programmes.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Screening Predictive MYC synthetic lethal screening reveals uncharacterized polo-like kinase 1 vulnerability in MYC high triple-negative breast cancer cells Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Bone-Derived Extracellular Matrices Modulate Osteosarcoma Drug Response and Invasive Phenotypes Preclinical models
University of Porto Porto, Portugal
up.pt Universities & institutes Public university in Portugal whose faculties of pharmacy and medicine and its i3S institute run cancer research.	Talk Fri Nov 20 3:15–3:25pm Part of Plenary Session 7: Proffered papers BBIT20, a first-in-class disruptor of BRCA1-BARD1 interaction, overcomes multidrug resistance in ovarian cancer Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs BBIT20 enhances anti-PD-1 efficacy by reshaping the tumor immune landscape in pancreatic cancer Drug design